Pα+ Psychedelic Bulletin #223: Ibogaine Advocates Court Trump, via Rogan; Compass Launches Provider Training Grants; Therapeutic Alliance Debate Reignites
- Rick Perry, Bryan Hubbard, and the Gospel of Ibogaine
- Compass Seeds Provider Training Programs
- Other Stories
- FDA’s FY2027 Budget Mentions Psychedelics and Confirms AdComm Shake-Up
- Colorado Rulemaking Process Draws Complaints on Proposed Changes to Fees and Procedures
- Does Therapeutic Alliance Matter in Psilocybin Therapy?
- Other Headlines
Rick Perry, Bryan Hubbard, and the Gospel of Ibogaine
Ibogaine has been in the news a great deal lately, with a New York Times journalist’s ibogaine trip appearing in a feature story last month and on Sunday’s episode of The Daily podcast.
On April 1st, ibogaine evangelists-in-chief Rick Perry and Bryan Hubbard appeared on the Joe Rogan Experience podcast. The episode, which comes in at just over two hours long, focuses on the work of Americans for Ibogaine, as well as a discussion of the drug more broadly.
We watched the full episode. Below, we share some key takeaways and weave recent developments in the area throughout…
Hubbard and Perry’s appearance was something of a reprise, as the pair were guests on the podcast last January to discuss the same topic. Back then, they previewed the Texas Ibogaine Initiative, a match-funding bill that was ultimately introduced last March.
In that January 2025 episode, the pair explained that the initiative would carve out $50M in state funding, to be matched by (a) private drug developer(s).
But as regular readers (and watchers of our Pα+ Q1 Briefing) will be well aware by now, that plan fell through, with the Texas Health and Human Services Commission declaring that ...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks